SC
BCRX icon

Scotia Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Scotia Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,352
Closed -$129K – 910
2025
Q2 		$129K Buy
+14,352
New +$134K ﹤0.01% 819
2024
Q4 		– Sell
-18,577
Closed -$141K – 863
2024
Q3 		$141K Buy
+18,577
New +$141K ﹤0.01% 794

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Scotia Capital's BCRX Position: Q3 2025 in Review

Scotia Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 14,352 shares — an estimated $129K sold.

Scotia Capital first reported a position in BCRX in Q3 2024 and held it in 2 quarters. The position peaked at $141K in Q3 2024. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Scotia Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Scotia Capital sold 14,352 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $129K.
  • Scotia Capital first reported a position in BioCryst Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Scotia Capital's BioCryst Pharmaceuticals position peaked at $141K in Q3 2024.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Scotia Capital's 13F filing for Q3 2025, filed 14 Nov 2025.